Sagimet Biosciences Inc.
Organization details
- Legal name
- Sagimet Biosciences Inc.
- Former names
- 3-V Biosciences, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Foster City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SGMT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001400118
- EIN
- 20-5991472
Board of directors
-
Anne M. Phillips · DirectorSince 2024
- Since 2023
-
David Happel · Director · President & CEOSince 2023
-
Eduardo Bruno Martins · DirectorSince 2023
-
Elizabeth A. Grammer · DirectorSince 2023
-
George Kemble · Director · Executive ChairmanSince 2023
- Since 2024
-
Jinzi Jason Wu · DirectorSince 2023
-
Merdad Parsey · DirectorSince 2023
-
Paul W. Hoelscher · DirectorSince 2024
-
Richard J. Rodgers · DirectorSince 2023
- Since 2024
Chief executives
Director election results
Annual meeting of June 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
71.7%
-
86.6%
-
96.4%
-
97.1%
Board connections
7 of this board's directors also sit on 20 other boards. 20 are in the same sector.
-
Ardelyx Inc. Same sectorvia Merdad Parsey and Richard J. Rodgers
-
Latigo Biotherapeutics Inc. Same sectorvia Beth C. Seidenberg and Timothy P. Walbert
-
Arcus Biosciences Inc. Same sectorvia Jennifer Jarrett
-
ArriVent BioPharma Inc. Same sectorvia Merdad Parsey
-
Atara Biotherapeutics Inc. Same sectorvia Beth C. Seidenberg
-
BioMarin Pharmaceutical Inc. Same sectorvia Timothy P. Walbert
-
Century Therapeutics Inc. Same sectorvia Timothy P. Walbert
-
Damora Therapeutics Inc. Same sectorvia Jennifer Jarrett
-
Kardigan Inc. Same sectorvia Timothy P. Walbert
-
Kyverna Therapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Mirum Pharmaceuticals Inc. Same sectorvia Timothy P. Walbert
-
Novavax Inc. Same sectorvia Richard J. Rodgers
-
Odyssey Therapeutics Inc. Same sectorvia Timothy P. Walbert
-
OnKure Therapeutics Inc. Same sectorvia Paul W. Hoelscher
-
Opus Genetics Inc. Same sectorvia Richard J. Rodgers
-
Progyny Inc. Same sectorvia Beth C. Seidenberg
-
Syndax Pharmaceuticals Inc. Same sectorvia Jennifer Jarrett
-
Vera Therapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Zura Bio Limited Same sectorvia Jennifer Jarrett
-
vTv Therapeutics Inc. Same sectorvia Anne M. Phillips
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,906,367
- 10 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14, 2026 | George Kemble Director | Option exercise | +326,618 | $6.36 | $2,077,290 |
| Aug 14, 2026 | George Kemble Director | Option exercise | +24,369 | $6.36 | $154,987 |
| Aug 14, 2026 | George Kemble Director | Open-market sale | −350,987 | $10.23 | $3,590,597 |
| Aug 11, 2026 | George Kemble Director | Option exercise | +9,751 | $6.36 | $62,016 |
| Aug 11, 2026 | George Kemble Director | Option exercise | +10,455 | $6.36 | $66,494 |
| Aug 11, 2026 | George Kemble Director | Open-market sale | −20,206 | $9.95 | $201,050 |
| Jul 20, 2026 | David Happel Director, Officer (President & CEO) | Open-market sale | −64,051 | $7.76 | $497,036 |
| Jul 20, 2026 | George Kemble Director | Open-market sale | −18,844 | $7.46 | $140,576 |
| Jul 20, 2026 | Rozek Elizabeth Officer (Chief Legal & Admin. Officer) | Open-market sale | −10,545 | $7.76 | $81,829 |
| Feb 19, 2026 | Rozek Elizabeth Officer (Chief Legal & Admin. Officer) | Grant or award | +44,000 | — | — |
| Feb 19, 2026 | Eduardo Bruno Martins Officer (Chief Medical Officer) | Grant or award | +44,000 | — | — |
| Feb 19, 2026 | David Happel Director, Officer (President & CEO) | Grant or award | +128,000 | — | — |
| Feb 19, 2026 | Chauche Thierry Officer (Chief Financial Officer) | Grant or award | +44,000 | — | — |
| Feb 10, 2026 | David Happel Director, Officer (President & CEO) | Open-market sale | −12,101 | $5.36 | $64,861 |
| Feb 10, 2026 | Chauche Thierry Officer (Chief Financial Officer) | Open-market sale | −1,312 | $5.36 | $7,032 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Sagimet Biosciences Inc.
Who is the CEO of Sagimet Biosciences Inc.?
David Happel has been Sagimet Biosciences Inc.'s President & CEO since July 2023.
How many directors are on Sagimet Biosciences Inc.'s board?
Sagimet Biosciences Inc.'s board has 12 directors: Anne M. Phillips, Beth C. Seidenberg, David Happel, Eduardo Bruno Martins, Elizabeth A. Grammer, George Kemble, Jennifer Jarrett, Jinzi Jason Wu, Merdad Parsey, Paul W. Hoelscher and 2 others.
Are Sagimet Biosciences Inc. insiders buying or selling shares?
Over the last 12 months, Sagimet Biosciences Inc. insiders made no open-market purchases and sold $4.9 million of shares in 10 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="sagimet-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.